Information to Shareholders

SDIR
For the transmission of Regulated Information Medica SpA uses the 1INFO-SDIR distribution system managed by Computershare S.p.A., with registered office at Milan, in Via L. Mascheroni 19.
Shareholding
  N° Shares %
Pelmo87 Srl 3,375,600 79.93%
Azimut Investments S.A. 228,100 5.40%
Free Float 619,550 14.67%
Total 4,223,250 100%
 
Information obligations of Significant Shareholders
 
Under the Euronext Growth Milan Regulation, anyone holding directly (participation in the share capital with voting rights) or through intermediary persons, trustees or subsidiaries (potential participation) or directly or through interposed persons, trustees or subsidiaries (aggregated participation) at least 5% of a category of financial instruments of Medica SpA is a "Significant Shareholder".
 
Exceeding the 5% threshold and achieving or exceeding (increasing or decreasing) the thresholds of 5%, 10%, 15%, 20%, 25%, 30%, 50%, 66.6 % and 90% constitute a "Substantial Change" that must be communicated by the Significant Shareholders to Medica SpA.
To this end, within 4 trading days, starting from the day on which the transaction involving the Substantial Change was carried out, the Significant Shareholder must notify Medica SpA:
  1. the identity of the significant shareholders involved
  2. the date on which Medica SpA was informed
  3. the date on which the Substantial Change occurred in the investments
  4. the price, amount and category of the Medica SpA financial instruments involved
  5. the nature of the operation
  6. the nature and extent of the Significant Shareholder's participation in the transaction.
The communication can be made using the attached form, sent by e-mail to giovanni.plasmati@medica.it and then sent in original by registered mail to: Medica SpA, Via Degli Artigiani, 7 - 41036 Medolla (MO) – ITALY.
 
(DOWNLOAD DOCUMENT)

 
The IPO TEAM is thus represented:
 
 

Intesa Sanpaolo
(
Divisione IMI Corporate & Investment Banking)

Global Coordinator & Joint Bookrunner
 

CFO SIM

Joint Bookrunner e Euronext Growth Advisor
 

DLA Piper

Studio Legale dell’Emittente
 

LCA Studio Legale

Studio Legale dei Joint Bookrunner
 

Epyon

Financial Advisor
  

EY

Società di Revisione
 

Hermes

Business Plan Advisor
 
2023
 
06 February 2023 Board of Directors for the presentation of preliminary consolidated results (Net Revenues and Net Financial Position) as of 31 December 2022
30 March 2023 Board of Directors for the approval of the draft financial statements and consolidated financial statements as of 31 December 2022
28 April 2023 Ordinary Shareholders’ Meeting for the approval of the financial statements for the year ended December 31, 2022 and for the presentation of the consolidated financial statement at December 31, 2022
04 August 2023 Board of Directors for the presentation of preliminary consolidated results (Net Revenues and Net Financial Position) as of 30 June 2023
28 September 2023 Board of Directors for the approval of the half-year report as of 30 June 2023 voluntarily subject to limited audit by the auditing firm
 
  2022
04 February 2022 Board of Directors for the presentation of preliminary consolidated results (Net Revenues and Net Financial Position) as of 31 December 2021
30 March 2022 Board of Directors for the approval of the draft financial statements and consolidated financial statements as of 31 December 2021
29 April 2022 Ordinary Shareholders’ Meeting for the approval of the financial statements for the year ended December 31, 2021 and for the presentation of the consolidated financial statement at December 31, 2021
05 August 2022 Board of Directors for the presentation of preliminary consolidated results (Net Revenues and Net Financial Position) as of 30 June 2022
28 September 2022 Board of Directors for the approval of the half-year report as of 30 June 2022 voluntarily subject to limited audit by the auditing firm